These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12228778)

  • 1. Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death.
    Heidenreich PA; Keeffe B; McDonald KM; Hlatky MA
    Am Heart J; 2002 Sep; 144(3):422-30. PubMed ID: 12228778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A; Sapp J
    Curr Cardiol Rep; 2017 Sep; 19(11):105. PubMed ID: 28900864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study.
    Cappato R
    Am J Cardiol; 1999 Mar; 83(5B):68D-73D. PubMed ID: 10089843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
    Cooley R; Akhtar M; Sra J
    Curr Cardiol Rep; 1999 Nov; 1(4):268-73. PubMed ID: 10980853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sudden cardiac death: who needs an implantable cardioverter-defibrillator and who needs antiarrhythmic drugs?
    Ferrari R; Cinca J; Marber M
    Eur Heart J; 1999 Mar; 20(6):397-8. PubMed ID: 10213339
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
    Haverkamp W; Eckardt L; Borggrefe M; Breithardt G
    Am J Cardiol; 1997 Oct; 80(8A):67G-73G. PubMed ID: 9354413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic therapies for the prevention of sudden cardiac death.
    McAlister FA; Teo KK
    Drugs; 1997 Aug; 54(2):235-52. PubMed ID: 9257080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death.
    Kamath GS; Mittal S
    Prog Cardiovasc Dis; 2008; 50(6):439-48. PubMed ID: 18474286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and prevention of sudden cardiac death--what have we learnt from randomised clinical trials?
    Kam RM; Teo WS; Koh TH; Lim YL
    Singapore Med J; 1999 Nov; 40(11):707-10. PubMed ID: 10709412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function?
    Block M; Hammel D; Böcker D; Borggrefe M; Breithardt G
    Am J Cardiol; 1996 Sep; 78(5A):62-8. PubMed ID: 8820838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada.
    Deniz HB; Ward A; Jaime Caro J; Alvarez P; Sadri H
    Curr Med Res Opin; 2009 Mar; 25(3):617-26. PubMed ID: 19232036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
    Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
    Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.
    Owens DK; Sanders GD; Heidenreich PA; McDonald KM; Hlatky MA
    Am Heart J; 2002 Sep; 144(3):440-8. PubMed ID: 12228780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic drugs or implantable cardioverter defibrillators in heart failure: the "poor heart".
    Böcker D; Breithardt G
    Am J Cardiol; 1999 Mar; 83(5B):83D-87D. PubMed ID: 10089846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major clinical trials assessing the prophylactic use of amiodarone in patients with ventricular tachyarrhythmias.
    Fogoros RN
    Control Clin Trials; 1996 Jun; 17(3 Suppl):37S-46S. PubMed ID: 8877266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death?
    Exner DV; Klein GJ
    J Cardiovasc Electrophysiol; 2003 Jun; 14(6):574-7. PubMed ID: 12875415
    [No Abstract]   [Full Text] [Related]  

  • 19. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden cardiac death prevention: antiarrhythmic drugs and the implantable cardioverter-defibrillator.
    Domanski MJ
    J Interv Cardiol; 1995 Feb; 8(1):9-15. PubMed ID: 10155222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.